Previous 10 | Next 10 |
Arena Pharmaceuticals (NASDAQ: ARNA ): Q4 GAAP EPS of -$1.76 misses by $0.22 . Revenue of $3M (-65.5% Y/Y) beats by $1.44M . Press Release More news on: Arena Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
SAN DIEGO , Feb. 26, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full-year ended December 31, 2019 . "As we continue to execute on near and mid-term operational object...
Arena Pharmaceuticals (NASDAQ: ARNA ) is scheduled to announce Q4 earnings results on Wednesday, February 26th, after market close. The consensus EPS Estimate is -$1.52 (-212.6% Y/Y) and the consensus Revenue Estimate is $1.56M (-82.1% Y/Y). Over the last 2 years, ARNA has beaten EPS ...
SAN DIEGO , Feb. 21, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on February 10, 2020 the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 132,100 shares of its common stock to 20 new...
SAN DIEGO , Feb. 20, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , President and Chief Executive Officer, will present at the upcoming investor conferences: SVB Leerink 9th Annual Global Healthcare Conference – Pres...
SAN DIEGO , Feb. 19, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its fourth quarter and full-year 2019 financial results and provide a corporate update on Wednesday, February 26, 2020 , after the close of the U.S. financial markets. The Company wil...
The Food and Drug Administration has asked Tokyo-based Eisai (OTC: ESALF) to withdraw its weight-loss drugs Belviq and the extended release formulation, Belviq XR, from the U.S. market. The Japanese drugmaker reluctantly complied, submitting a request to voluntarily withdraw the drug. When ...
Citing its potential cancer risk, the FDA has requested the removal of Arena Pharmaceuticals' ( ARNA -1.1% ) Belviq (lorcaserin) from the U.S. market. More news on: Arena Pharmaceuticals, Inc., Eisai Co., Ltd., Healthcare stocks news, Stocks on the move, Read more ...
SAN DIEGO , Feb. 11, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will present new data from the open-label extension (OLE) of the Phase 2 OASIS trial for its investigative drug candidate etrasimod, a next-generation, once-daily, oral, selective sph...
AdaptHealth (NASDAQ: AHCO ) initiated with Buy rating and $17 (31% upside) price target at Stifel. More news on: AdaptHealth Corp., DURECT Corporation, InMed Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Arena Pharmaceuticals Inc. Company Name:
ARNA Stock Symbol:
NASDAQ Market:
Arena Pharmaceuticals Inc. Website:
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded at a new 52-week high today of $99.95. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares. Arena Pharmaceuticals is a biotechnology company targeting G-protein-couple...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 52-week high of $98.57. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Over the past year, Arena Pharmaceuticals Inc. has traded in a range of $45...